

HEMATOPATHOLOGY TEST REQUISITION FORM

For Solid Tumor and Liquid Biopsy testing, kindly complete and return the Solid Tumor and Liquid Biopsy requisition forms.

PATIENT INFORMATION (REQUIRED)

Name Last _____ First _____
Date of Birth ____/____/____
Street _____
City _____ State _____ ZIP _____
MRN / Patient ID# _____
Phone# _____

For Bone Marrow Transplant Patients Only:

Donor Gender Male Female

SPECIMEN INFORMATION (REQUIRED)

Collection date ____/____/____ Time _____ AM PM
Sent date ____/____/____ Perform CBC in house
 CBC results attached (required for Blood and Bone Marrow)
 Bone Marrow, [tube(s)] # _____ Peripheral Blood, [tube(s)] # _____
 Fresh Tissue/Fluid, [tube(s)] # _____ Slide(s): _____
 Formalin Container(s) # _____ Paraffin Block (s) # _____
 Other Container(s) # _____ Other # _____ Specify: _____

MOBILE PHLEBOTOMY REQUEST (Oncology Office to Complete if Needed)

Patient Phone (mobile preferred): _____
Patient Email (optional): _____
Patient Home Address: _____
City, ST, ZIP: _____

siParadigm Liquid Biopsy collection and shipping kit was provided to the patient. Please fax this completed requisition, pathology report, and insurance information to 888-890-4774 | By completing this section, Client represents it has obtained patient's consent to be contacted by third-party service.

PHYSICIAN INFORMATION (REQUIRED)

Referring MD _____
Attending/Ordering MD _____
Account Information _____

BILLING INFORMATION (BOTH SIDES REQUIRED)

Insurance Non-hospital/office patient
 Client Out-patient hospital
 Patient In-patient hospital Discharge Date ____/____/____
 Independent ambulatory clinic/surgical center

ICD-10 Code (REQUIRED) _____

Notes: _____

Attach clinical notes, patient information, CBC, and insurance card (REQUIRED)

LEVEL OF SERVICE (REQUIRED)

siPortfolio™
Hematopathologist will select FLOW, IHC, FISH, Karyotype and/or Molecular testing as clinically needed for diagnosis, prognosis and therapeutics.
DO NOT mark any individual test(s)

Perform Marked Test(s) Only
Only check if you DO NOT choose siPortfolio

TAT varies according to test(s) chosen. Please see back for details

STAGE OF DISEASE (REQUIRED)

New Diagnosis Staging Evaluation Remission Relapse Measurable Residual Disease (MRD) Follow-up/Monitoring

LIST OF DISEASES & FINDINGS

| DISEASES | FINDINGS | DISEASES TO BE RULED OUT |
|--|---|--|
| <input type="checkbox"/> ALL | <input type="checkbox"/> Anemia | <input type="checkbox"/> Rule out MDS |
| <input type="checkbox"/> AML | <input type="checkbox"/> Eosinophilia | <input type="checkbox"/> Rule out Myeloma |
| <input type="checkbox"/> CLL | <input type="checkbox"/> Erythrocytosis | <input type="checkbox"/> Rule out MPN |
| <input type="checkbox"/> CML, Follow-up | <input type="checkbox"/> Leukocytes, Atypical | <input type="checkbox"/> Rule out LPD |
| <input type="checkbox"/> CML, New diagnosis | <input type="checkbox"/> Leukocytosis | <input type="checkbox"/> Rule out Leukemia |
| <input type="checkbox"/> LPD | <input type="checkbox"/> Lymphopenia | <input type="checkbox"/> Rule out Myeloma |
| <input type="checkbox"/> Lymphoma, Hodgkin | <input type="checkbox"/> Lymphadenopathy | <input type="checkbox"/> Others: _____ |
| <input type="checkbox"/> Lymphoma, non-Hodgkin | <input type="checkbox"/> Lymphocytosis | |
| <input type="checkbox"/> Myeloma (□MRD) | <input type="checkbox"/> Thrombocytopenia | |
| <input type="checkbox"/> Marrow infiltration | <input type="checkbox"/> Thrombocytosis | |
| <input type="checkbox"/> MDS | | |
| <input type="checkbox"/> MNH | | |
| <input type="checkbox"/> Other: _____ | | |

LIST OF INDIVIDUAL TESTS

(See website www.siparadigm.com/compendium/ for detailed panel content)

MORPHOLOGY siPortfolio™
 Perform CBC
 Peripheral smear review
 Bone marrow biopsy and aspirate, including special and immunostains

FLOW CYTOMETRY siPortfolio™ Required: Please specify the level of service
 (G) Global (T) Tech-Only (P) Professional Only
 Leukemia/Lymphoma screen panel with reflex to disease-specific panels
 Myeloma (□MRD)
 CLL (□MRD)
 MNH
 Other (specify): _____

CYTOGENETICS KARYOTYPE siPortfolio™
 Myeloid T-Lymphoid B-Lymphoid

CYTOGENETICS FISH siPortfolio™
 (G) Global (T) Tech-Only
 ALL CML Lymphoma MZL
 AML DLBCL Mantle Waldenström
 APL Eosinophilia MDS Other: _____
 Burkitt Follicular MPN
 CLL High Grade B-cell Myeloma
Specimen Hold Option: Direct Harvest and Hold (see details at the back)

MOLECULAR siPortfolio™ (See detailed panels content at the back)
 Myeloid Focused, DNA
 Myeloid Comprehensive, DNA
 AML/Eosinophilia, DNA/RNA
 Lymphoid
Specimen Hold Options: Extract and hold DNA/RNA (see details at the back)

Individual Genes (See website under physician tab for a complete list)

*Tests performed by PCR

ABL Kinase Mutation (CML) BRAF (HCL)* FLT3 ITD & TKD* JAK2 Exons 13 & 15* MYD88 (WM)* STAT3 and STAT5B (clonal LGL)
 B-cell clonality study (IGH)* CALR* IDH1/IDH2 JAK2 V617F* NPM1 TP53
 BCR-ABL, Major (CML)* CSF3R IGHV hypermutation KIT D816X* PML-RARA, Quant T-cell clonality study (gamma with reflex to beta)
 BCR-ABL, Minor (ALL)* CXCR4 (WM) JAK2 Exon 12* MPL* SF3B1 Other: _____

Reflexes (as clinically indicated)

*Tests performed by PCR

JAK2 V617F* with reflex to:
 Polycythemia vera panel (JAK2 exon 12, 13 & 15)
 CALR*/MPL* with or without the entire myeloid panel as clinically indicated
 Major BCR-ABL Quantitative (p210 M-bcr)* with reflex to:
 Minor BCR-ABL Quantitative (p190 m-bcr)*
 ABL kinase domain resistance mutations panel

PHYSICIAN SIGNATURE (REQUIRED)

Confirmation of Informed Consent & Statement of Medical Necessity: I affirm each of the following: 1) Testing is medically necessary for the diagnosis of a disease or syndrome. 2) The results will be used in the patient's medical management and treatment decisions. 3) The person listed as the ordering physician is authorized by law to order the test(s) requested herein. 4) I have provided genetic testing information to the patient and the patient has consented to such testing (if applicable).

I am certified to order the test (s) listed above, such that these test (s) are medically necessary and I have obtained informed consent for the requested test (s) when pertinent.

Signature *(MANDATORY FOR TESTING) _____ Date _____

ADDITIONAL INFORMATION (REQUIRED)

Gender Identity: Male Female

Ethnicity: African-American Jewish-Ashkenazi Adopted Asian Caucasian/NW European Jewish-Sephardic Native American Hispanic Middle Eastern Unknown Asked but Unknown Other _____ Non-Hispanic or Non-Latino Choose not to disclose

Race: American Indian or Alaska Native Black or African American Asian Native Hawaiian or Other Pacific Islander White Other _____ Unknown Asked but Unknown Choose not to disclose

Billing Information:

Terms and Conditions of Requisition Form

Any organization ("Client") referring specimens pursuant to this Requisition Form agrees to the following terms and conditions:

- 1. Binding Agreement:** This Requisition Form constitutes a contractually binding order for the services and/or tests requested. The Client acknowledges and agrees that it is financially responsible for all tests designated as billable to the Client herein.
- 2. Third-Party Billing and Client Financial Responsibility:**
The Client must accurately indicate on the front of this Requisition Form whether:
 - The Client should be billed directly (e.g., when services are provided under non-fee-for-service models such as capitated agreements, Diagnosis-Related Groups [DRGs], or any bundled or consolidated payment arrangements), **or**
 - The services should be billed to a federal, state, or commercial health insurer, or other third party (collectively referred to as "Payers").

For all services intended to be billed to Payers, the Client agrees to provide complete and accurate billing information necessary for siParadigm to process such claims.

siParadigm reserves the right to bill the Client directly under the following circumstances:

- Required billing information is not provided within ten (10) days of the date the services are reported,
- The patient lacks valid Payer coverage, or
- The Payer denies financial responsibility for the services and indicates that the Client is responsible.

Specimen Requirements:

Specimens should be refrigerated if they are not shipped immediately. During transport, please ensure the use of a cold pack to maintain proper temperature.

For inquiries regarding specimen requirements or shipping instructions within the United States, please contact our Client Services team at ☎ 201-599-9044 or 888-599-5227, or via email at ✉ cs@siparadigm.com. For clients in Puerto Rico, please contact us at ☎ 888-782-5430 or email ✉ cs.pr@siparadigm.com.

Detailed information on specimen-specific requirements can be found on our website 🌐 <https://www.siparadigm.com>

For packaging conditions and the required specimen quantity per test, please check our website:

🌐 <https://www.siparadigm.com/physician-support/specimen-requirements>

siParadigm is not responsible for any difference in quantity of specimen if it is not indicated

Specimen Hold Option Descriptions

To preserve the integrity of samples and avoid unnecessary testing, siParadigm Laboratory offers the option of processing samples to maintain specimen integrity for extended periods, without a test order. Specimen Hold Options include:

FISH:

Direct Harvest and Hold: Sample should be received at siParadigm Laboratory within 120 hours of collection. Specimens will be minimally processed and directly harvested while the cells are still viable. Analysis is not performed until the client test order is received. Processed samples will be retained for 28 days.

Molecular Testing: Extract Nucleic Acid and Hold: Nucleic acid (DNA or RNA or TNA) will be isolated from viable cells and stored in a freezer. Use this option when it is known which test(s) may be added. Analysis is not performed until the client test order is received. Processed samples will be retained for 28 days.

Add-Ons:

To request add-ons to existing cases, please complete the form on our website/webportal or reach out to our Customer Service team:

- **United States:** ☎ 201-599-9044 or 888-599-5227, ☎ 201-599-9066 | ✉ cs@siparadigm.com
- **Puerto Rico:** ☎ 888-782-5430, ☎ 866-369-4114 | ✉ cs.pr@siparadigm.com
- **The form is available at:** 🌐 www.siparadigm.com/physician-support/physician-requisition-forms

Pick-Ups:

To arrange a pickup, please contact our Customer Service department:

- **United States:** ☎ 201-599-9044 or 888-599-5227 | ✉ cs@siparadigm.com
- **Puerto Rico:** ☎ 888-782-5430 | ✉ cs.pr@siparadigm.com

Detailed Molecular Panels

| Myeloid Focused, DNA | | | Myeloid Comprehensive, DNA | | | | AML/Eosinophilia, DNA/RNA | | | | Lymphoid | | |
|----------------------|--------|--------|----------------------------|--------|---------|--------|---------------------------|---------|---------|-------|----------|---------|----------|
| ABL1 | ΔIKZF1 | SRSF2 | ABL1 | FBXW7 | NPM1 | STAT3 | *ABL1 | FLT3 | *MYH11 | SMC1A | ΔATM | GNA13 | ΔSOCS1 |
| ΔASXL1 | JAK2 | ΔSTAG2 | ANKRD26 | FLT3 | NRAS | STAT5B | *ALK | *FUS | NF1 | SMC3 | B2M | ID3 | STAT3 |
| ΔBCOR | KIT | STAT3 | ΔASXL1 | GATA1 | PAX5 | ΔTET2 | ANKRD26 | GATA2 | NPM1 | SRSF2 | BCL2 | ΔIDH2 | STAT5B |
| BCORL1 | KRAS | STAT5B | ΔBCOR | GATA2 | ΔPHF6 | ΔTP53 | ASXL1 | *HMGA2 | NRAS | STAT2 | ΔBCL6 | ΔIRF4 | STAT6 |
| BRAF | MPL | ΔTET2 | BCORL1 | GNAS | PIGA | U2AF1 | *BCL2 | HRAS | *NTRK3 | *TCF3 | BIRC3 | ΔKMT2D | ΔTENT5C |
| ΔCALR | MYD88 | ΔTP53 | BRAF | GNB1 | PPM1D | U2AF2 | BCOR | IDH1 | *NUP214 | TET2 | BRAF | MAP2K1 | ΔTET2 |
| CBL | ΔNF1 | U2AF1 | ΔCALR | HRAS | ΔPRPF8 | UBA1 | *BRAF | IDH2 | *NUP98 | *TFE3 | BTK | MYC | TNFAIP3 |
| ΔCEBPA | NOTCH1 | WT1 | CBL | IDH1 | PTEN | WT1 | CALR | IKZF1 | *PDGFRA | TP53 | CARD11 | MYD88 | TNFRSF14 |
| CSF3R | NPM1 | ΔZRSR2 | CBLB | IDH2 | PTPN11 | XPO1 | CBL | *JAK2 | *PDGFRB | U2AF1 | CCND1 | NFKBIE | ΔTP53 |
| CXCR4 | NRAS | | CBLC | ΔIKZF1 | ΔRB1 | ΔZRSR2 | *CCND1 | KIT | PHF6 | WT1 | ΔCCND3 | NOTCH1 | XPO1 |
| DDX41 | ΔPHF6 | | CDKN2A | IL7R | ΔRUNX1 | | CEBPA | *KMT2A | PPM1D | ZRSR2 | CD79B | NOTCH2 | |
| DNMT3A | PIGA | | ΔCEBPA | JAK1 | SETBP1 | | *CREBBP | (MLL) | PRPF8 | | CREBBP | ΔPAX5 | |
| ΔETV6 | PPM1D | | CSF3R | JAK2 | SF3A1 | | CSF3R | KRAS | PTPN11 | | CXCR4 | ΔPIM1 | |
| ΔEZH2 | ΔPRPF8 | | CUX1 | JAK3 | SF3B1 | | DDX41 | *MET | *RARA | | DNMT3A | ΔPLCG2 | |
| FLT3 | PTPN11 | | CXCR4 | KIT | ΔSH2B3 | | DNMT3A | *MECOM | RB1 | | EP300 | PRDM1 | |
| GATA1 | ΔRB1 | | DDX41 | KRAS | SMARCB1 | | *EGFR | *MLLT10 | *RBM15 | | ΔEZH2 | ΔPTEN | |
| GATA2 | ΔRUNX1 | | DNMT3A | MPL | SMC1A | | *ETV6 | *MLLT3 | *RUNX1 | | ETV6 | ΔRHOA | |
| HRAS | SETBP1 | | ETNK1 | MYD88 | SMC3 | | EZH2 | MPL | SETBP1 | | FAS | RPS15 | |
| IDH1 | SF3B1 | | ΔETV6 | ΔNF1 | SRSF2 | | *FGFR1 | *MYBL1 | SF3B1 | | FBXW7 | ΔSAMHD1 | |
| IDH2 | ΔSH2B3 | | ΔEZH2 | NOTCH1 | ΔSTAG2 | | *FGFR2 | MYD88 | SH2B3 | | FOXO1 | ΔSF3B1 | |

Δ indicate full genes (17)

Δ indicate full genes (17)

* Indicates fusion driver genes (30)

Δ indicate genes covered full coding sequences (19)